Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | PPOX | P50336 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | USP8 | P40818 | 2/20 | 0.39 |
| ▸ | USP7 | Q93009 | 2/20 | 0.39 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976245 | 0.92 | HSP90AA1 (0.53) | S100A4HSP90AA1PPOXPTPN1PTPN11 | |
| SCHEMBL9629435 | 0.80 | S100A4 (0.61) | S100A4HSP90AA1PPOXPTPN1PTPN11 | |
| SCHEMBL29407366 | 0.80 | ESR2 (0.61) | USP7USP47KDM4EALDH1A1CYP3A4 | |
| SCHEMBL5817037 | 0.80 | ESR2 (0.61) | USP7USP47KDM4EALDH1A1CYP3A4 | |
| SCHEMBL18992102 | 0.78 | KDM4E (0.38) | S100A4HSP90AA1CES1KDM4EALDH1A1 | |
| SCHEMBL30003252 | 0.78 | KDM4E (0.38) | S100A4HSP90AA1CES1KDM4EALDH1A1 | |
| SCHEMBL10086888 | 0.77 | CA9 (0.44) | PTPN1USP8USP7USP47KDM4E | |
| SCHEMBL21013875 | 0.77 | TGM2 (0.39) | CES1TGM2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL18992188 | 0.77 | BCL2 (0.58) | S100A4CES1TGM2KDM4EALDH1A1 | |
| SCHEMBL28591550 | 0.77 | MAOA (0.53) | KDM4EALDH1A1CYP3A4MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0007985-B1 | 6-CHLORO-2,3-DIHYDROXY-1,4-NAPHTHOQUINONE AND ITS 2,3-DIESTERS, AND THEIR PREPARATION | SYNTEX (U.S.A.) INC. (US) | 1982-09-01 | — | — | EP | claimed |
| EP-0007985-A1 | 6-Chloro-2,3-dihydroxy-1,4-naphthoquinone and its 2,3-diesters, and their preparation | SYNTEX (U.S.A.) INC. (US) | 1980-02-20 | — | — | EP | claimed |
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190071380-A1 | NAPHTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071380-A1 | NAPHTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2017106624-A1 | NAPTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106624-A1 | NAPTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-22 | — | — | WO | disclosed |
| US-8871802-B2 | Naphthoquinones for disease therapies | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2013-06-13 | — | — | US | disclosed |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2013-06-13 | — | — | US | disclosed |
| EP-0644878-A1 | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994029275-A1 | BENZ(B)AZEPINE-2,5-DIONES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | ZENECA LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
| WO-1993025534-A1 | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-23 | — | — | WO | disclosed |
| US-5254683-A | Neurological disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0517876-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS. | ICI PLC (GB) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992011854-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-23 | — | — | WO | disclosed |
| EP-0007985-B1 | 6-CHLORO-2,3-DIHYDROXY-1,4-NAPHTHOQUINONE AND ITS 2,3-DIESTERS, AND THEIR PREPARATION | SYNTEX (U.S.A.) INC. (US) | 1982-09-01 | — | — | EP | disclosed |
| US-4255405-A | 2,3-DIESTERS | SYNTEX (U.S.A.) INC. (US) | 1981-03-10 | — | — | US | disclosed |
| EP-0007985-A1 | 6-Chloro-2,3-dihydroxy-1,4-naphthoquinone and its 2,3-diesters, and their preparation | SYNTEX (U.S.A.) INC. (US) | 1980-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | NQO1, RECQL, ABCB1 | S100A4 2683/4885HSP90AA1 1460/4885PPOX 1281/4885 |
| US-20190071380-A1 | NAPHTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | NQO1, RECQL, ABCB1 | S100A4 2683/4885HSP90AA1 1460/4885PPOX 1281/4885 |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | NQO1, NME2, CYP27B1 | S100A4 2159/4885HSP90AA1 1319/4885PPOX 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.